CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,276,399 | -41.6% | 50,152 | -27.8% | 0.02% | -35.5% |
| Q2 2023 | $3,899,765 | +14.9% | 69,465 | -7.4% | 0.03% | +6.9% |
| Q1 2023 | $3,392,929 | +1.7% | 75,015 | -8.6% | 0.03% | 0.0% |
| Q4 2022 | $3,335,414 | -34.3% | 82,052 | +5.7% | 0.03% | -37.0% |
| Q3 2022 | $5,074,000 | +13.7% | 77,649 | +5.7% | 0.05% | +31.4% |
| Q2 2022 | $4,463,000 | -6.1% | 73,453 | -3.0% | 0.04% | +20.7% |
| Q1 2022 | $4,755,000 | -27.0% | 75,753 | -11.9% | 0.03% | -14.7% |
| Q4 2021 | $6,513,000 | -11.0% | 85,939 | +31.5% | 0.03% | -22.7% |
| Q3 2021 | $7,317,000 | +42.5% | 65,373 | +106.1% | 0.04% | +46.7% |
| Q2 2021 | $5,136,000 | +34.4% | 31,722 | +1.1% | 0.03% | +20.0% |
| Q1 2021 | $3,822,000 | +32.6% | 31,370 | +66.6% | 0.02% | +38.9% |
| Q4 2020 | $2,883,000 | – | 18,831 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |